These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35890100)

  • 21. The complementary effects of atorvastatin and exercise treatment on the composition and stability of the atherosclerotic plaques in ApoE knockout mice.
    Moustardas P; Kadoglou NP; Katsimpoulas M; Kapelouzou A; Kostomitsopoulos N; Karayannacos PE; Kostakis A; Liapis CD
    PLoS One; 2014; 9(9):e108240. PubMed ID: 25264981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability.
    Müller A; Krämer SD; Meletta R; Beck K; Selivanova SV; Rancic Z; Kaufmann PA; Vos B; Meding J; Stellfeld T; Heinrich TK; Bauser M; Hütter J; Dinkelborg LM; Schibli R; Ametamey SM
    Nucl Med Biol; 2014 Aug; 41(7):562-9. PubMed ID: 24853402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor necrosis factor-α regulates triggering receptor expressed on myeloid cells-1-dependent matrix metalloproteinases in the carotid plaques of symptomatic patients with carotid stenosis.
    Rao VH; Rai V; Stoupa S; Subramanian S; Agrawal DK
    Atherosclerosis; 2016 May; 248():160-9. PubMed ID: 27017522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 and tissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization.
    Cevik C; Otahbachi M; Nugent K; Warangkana C; Meyerrose G
    J Cardiovasc Med (Hagerstown); 2008 Dec; 9(12):1274-8. PubMed ID: 19001938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
    Müller-Wieland D; Leiter LA; Cariou B; Letierce A; Colhoun HM; Del Prato S; Henry RR; Tinahones FJ; Aurand L; Maroni J; Ray KK; Bujas-Bobanovic M
    Cardiovasc Diabetol; 2017 May; 16(1):70. PubMed ID: 28545518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians.
    Trentman TL; Avey SG; Ramakrishna H
    J Anaesthesiol Clin Pharmacol; 2016; 32(4):440-445. PubMed ID: 28096572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of PCSK9 in Homocysteine-Accelerated Lipid Accumulation in Macrophages and Atherosclerosis in ApoE
    Jin P; Gao D; Cong G; Yan R; Jia S
    Front Cardiovasc Med; 2021; 8():746989. PubMed ID: 34660746
    [No Abstract]   [Full Text] [Related]  

  • 28. Regression in carotid plaque lipid content and neovasculature with PCSK9 inhibition: A time course study.
    Lepor NE; Sun J; Canton G; Contreras L; Hippe DS; Isquith DA; Balu N; Kedan I; Simonini AA; Yuan C; Hatsukami TS; Zhao XQ
    Atherosclerosis; 2021 Jun; 327():31-38. PubMed ID: 34038761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Furin-like proprotein convertases are central regulators of the membrane type matrix metalloproteinase-pro-matrix metalloproteinase-2 proteolytic cascade in atherosclerosis.
    Stawowy P; Meyborg H; Stibenz D; Borges Pereira Stawowy N; Roser M; Thanabalasingam U; Veinot JP; Chrétien M; Seidah NG; Fleck E; Graf K
    Circulation; 2005 May; 111(21):2820-7. PubMed ID: 15911696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between pulse pressure with plasma PCSK9 and interleukin-6 among patients with acute ischemic stroke and dyslipidemia.
    Chang CS; Kuo CL; Huang CS; Cheng YS; Lin SS; Liu CS
    Brain Res; 2022 Nov; 1795():148080. PubMed ID: 36088960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review.
    Wu NQ; Shi HW; Li JJ
    Front Cardiovasc Med; 2022; 9():763516. PubMed ID: 35252378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of cytokines on matrix metalloproteinases produced by fibroblasts cultured in monolayer and collagen gels.
    Wong WR; Kossodo S; Kochevar IE
    J Formos Med Assoc; 2001 Jun; 100(6):377-82. PubMed ID: 11480246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study).
    Liu YQ; Li DD; Chai M; Cong HL; Cong XQ; Dai J; DU RP; Gao M; Guo JC; Guo YQ; Hong XJ; Huang RC; Jia FS; Li JY; Li Q; Liu JM; Liu XP; Liu YG; Nie HG; Shao B; Shen XY; Song HQ; Song YJ; Wang LJ; Wang S; Wu DM; Xia J; Yang ZY; Yu HY; Zhang H; Zhang TM; Zhao JY; Zhao LC; Zheng MQ; Chen YD
    J Geriatr Cardiol; 2021 Apr; 18(4):261-270. PubMed ID: 33995505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Changes in proinflammatory cytokine and destructive metalloproteinase levels during formation of unstable atherosclerotic plaque].
    Ragino IuI; Cherniavskiĭ AM; Polonskaia IaV; Volkov AM; Semaeva EV; Tsymbal SIu; Voevoda MI
    Kardiologiia; 2009; 49(6):43-9. PubMed ID: 19656094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytokines regulate matrix metalloproteinases in human uterine endometrial fibroblast cells through a mechanism that does not involve increases in extracellular matrix metalloproteinase inducer.
    Braundmeier AG; Nowak RA
    Am J Reprod Immunol; 2006 Sep; 56(3):201-14. PubMed ID: 16911716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome.
    Peeters W; Moll FL; Vink A; van der Spek PJ; de Kleijn DP; de Vries JP; Verheijen JH; Newby AC; Pasterkamp G
    Eur Heart J; 2011 Sep; 32(18):2314-25. PubMed ID: 21289041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carotid thickness and atherosclerotic plaque stability, serum inflammation, serum MMP-2 and MMP-9 were associated with acute cerebral infarction.
    Chen L; Yang Q; Ding R; Liu D; Chen Z
    Exp Ther Med; 2018 Dec; 16(6):5253-5257. PubMed ID: 30542482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms.
    Katsuki S; K Jha P; Lupieri A; Nakano T; Passos LSA; Rogers MA; Becker-Greene D; Le TD; Decano JL; Ho Lee L; Guimaraes GC; Abdelhamid I; Halu A; Muscoloni A; V Cannistraci C; Higashi H; Zhang H; Vromman A; Libby P; Keith Ozaki C; Sharma A; Singh SA; Aikawa E; Aikawa M
    Circ Res; 2022 Nov; 131(11):873-889. PubMed ID: 36263780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes.
    Liberale L; Montecucco F; Camici GG; Dallegri F; Vecchie A; Carbone F; Bonaventura A
    Curr Med Chem; 2017; 24(14):1403-1416. PubMed ID: 28260498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proprotein convertase subtilisin/kexin type 9 and mortality in patients starting hemodialysis.
    Strålberg T; Nordenskjöld A; Cao Y; Kublickiene K; Nilsson E
    Eur J Clin Invest; 2019 Jul; 49(7):e13113. PubMed ID: 30921469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.